{"id":14732,"date":"2026-11-06T08:00:00","date_gmt":"2026-11-06T07:00:00","guid":{"rendered":"https:\/\/www.msd.ch\/de\/?post_type=news_item&#038;p=14732"},"modified":"2026-11-05T16:07:47","modified_gmt":"2026-11-05T15:07:47","slug":"zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs","status":"publish","type":"news_item","link":"https:\/\/www.msd.ch\/de\/news\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\/","title":{"rendered":"Swissmedic erteilt Zulassung f\u00fcr KEYTRUDA\u00ae (Pembrolizumab) in Kombination mit Enfortumab vedotin (EV), als Behandlung vor und nach einer Operation bei Erwachsenen mit muskelinvasivem Blasenkrebs (MIBC)."},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[30],"class_list":["post-14732","news_item","type-news_item","status-publish","post-password-required","hentry","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei Blasenkrebs | MSD<\/title>\n<meta name=\"description\" content=\"Swissmedic l\u00e4sst KEYTRUDA\u00ae in Kombination mit Enfortumab vedotin zur perioperativen Behandlung von muskelinvasivem Blasenkrebs zu.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/de\/news\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei Blasenkrebs | MSD\" \/>\n<meta property=\"og:description\" content=\"Swissmedic l\u00e4sst KEYTRUDA\u00ae in Kombination mit Enfortumab vedotin zur perioperativen Behandlung von muskelinvasivem Blasenkrebs zu.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/de\/news\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/news\\\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\\\/\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/news\\\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\\\/\",\"name\":\"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei Blasenkrebs | MSD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/#website\"},\"datePublished\":\"2026-11-06T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/news\\\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/\",\"name\":\"msd.ch\",\"description\":\"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei Blasenkrebs | MSD","description":"Swissmedic l\u00e4sst KEYTRUDA\u00ae in Kombination mit Enfortumab vedotin zur perioperativen Behandlung von muskelinvasivem Blasenkrebs zu.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/de\/news\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\/","og_locale":"en_US","og_type":"article","og_title":"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei Blasenkrebs | MSD","og_description":"Swissmedic l\u00e4sst KEYTRUDA\u00ae in Kombination mit Enfortumab vedotin zur perioperativen Behandlung von muskelinvasivem Blasenkrebs zu.","og_url":"https:\/\/www.msd.ch\/de\/news\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\/","og_site_name":"msd.ch","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/de\/news\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\/","url":"https:\/\/www.msd.ch\/de\/news\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\/","name":"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei Blasenkrebs | MSD","isPartOf":{"@id":"https:\/\/www.msd.ch\/de\/#website"},"datePublished":"2026-11-06T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.msd.ch\/de\/news\/zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-als-perioperative-behandlung-bei-erwachsenen-mit-muskelinvasivem-blasenkrebs\/#breadcrumb"},"inLanguage":"en-US"},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/de\/#website","url":"https:\/\/www.msd.ch\/de\/","name":"msd.ch","description":"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/14732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":7,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/14732\/revisions"}],"predecessor-version":[{"id":14755,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/14732\/revisions\/14755"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media?parent=14732"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/tags?post=14732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}